.png)
Metformin, a widely used diabetes medication, also plays a role in aging and disease prevention by influencing IGF-1 (Insulin-like Growth Factor 1), a hormone critical for growth and metabolism. Here's what research reveals:
- Metformin's Effect on IGF-1: Studies show mixed results. In children, short-term treatment significantly lowers IGF-1, while adults may see slight increases. Long-term effects remain unclear.
- Dosage Matters: Higher doses (e.g., 2,000 mg/day) lead to greater IGF-1 reductions, but results vary by age and health conditions.
- Mechanisms: Metformin activates AMPK, disrupting IGF-1's growth pathways, reducing cancer risks, and promoting healthier aging.
- Benefits vs. Risks: Lower IGF-1 may reduce cancer risks and improve heart health, but excessively low levels can harm metabolic health.
Future research needs to address long-term effects, optimal dosages, and individual differences to maximize metformin’s potential for aging and health.
Growth Hormone, DHEA & Metformin in Aging (clinical study)
What Studies Show About Metformin's Effects on IGF-1 Levels
Metformin's impact on IGF-1 levels can vary depending on factors like age, treatment duration, and dosage. A meta-analysis of 11 studies involving 569 participants found a slight, non-significant average decrease in IGF-1 levels, with a weighted mean difference of –8.292 ng/mL. However, this overall result doesn't tell the whole story. When researchers examined specific groups and treatment protocols, distinct patterns emerged, influenced by age, time, and dosage.
Effects in Different Age Groups
Age appears to play a significant role in how metformin affects IGF-1 levels. In children aged 18 or younger who were treated for less than 12 weeks, IGF-1 levels dropped significantly by –55.402 ng/mL. On the other hand, adults over 18 experienced an increase of 15.125 ng/mL, while children in longer-term studies (beyond 12 weeks) showed minimal changes, with an average reduction of –1.038 ng/mL. Interestingly, studies involving resistance training found that IGF-1 levels increased significantly in participants over 60 years old.
Changes Over Time
The duration of metformin treatment also influences its effects. Research suggests that the most notable changes in IGF-1 levels occur in the first few months of treatment, with these effects potentially diminishing over time. For example, the SPIRIT trial, led by Hsin-Chieh "Jessica" Yeh at Johns Hopkins University, studied 121 cancer survivors with overweight or obesity between August 2015 and December 2016. Participants were divided into groups receiving self-directed weight loss, coach-directed weight loss, or metformin (up to 2,000 mg daily).
After three months, those in the metformin group showed a significant IGF-1 reduction compared to the self-directed group, with a mean difference of –5.5 ng/mL (P = 0.02). At six months, the reduction remained significant for participants with obesity (mean difference of –7.2 ng/mL) but was no longer evident in overweight individuals. This suggests that baseline body composition may influence how long metformin's effects on IGF-1 persist.
"Some previous short-term studies showed metformin treatment reduced IGF-I levels in patients with endometrial cancer, in women with polycystic ovary syndrome, and in healthy men... Our findings were consistent with those studies, and additionally suggested that the effect from metformin on IGF-I levels may diminish over time."
– Hsin-Chieh "Jessica" Yeh, PhD, associate professor of medicine, epidemiology and oncology at Johns Hopkins University
How Dose Affects IGF-1 Response
Dosage is another critical factor in determining metformin's impact on IGF-1 levels. Evidence from the SPIRIT trial indicates a clear dose-dependent relationship, where higher doses lead to more significant reductions in IGF-1. At the three-month mark, the following results were observed:
| Average Daily Dose | IGF-1 Change (ng/mL) | 95% Confidence Interval |
|---|---|---|
| 500 mg | –2.61 | –4.64 to –0.57 |
| 1,000 mg | –4.00 | –7.34 to –0.65 |
| 1,500 mg | –5.38 | –10.14 to –0.63 |
| 2,000 mg | –6.77 | –12.98 to –0.56 |
Every dose level produced statistically significant IGF-1 reductions (P < 0.05). Notably, doubling the dose from 1,000 mg to 2,000 mg nearly doubled the reduction in IGF-1, underscoring the importance of dose adjustments to meet specific therapeutic goals. However, individual factors like age, body composition, and treatment duration must also be considered when tailoring dosages.
How Metformin Changes IGF-1 and Growth Hormone Function
Metformin influences IGF-1 (Insulin-like Growth Factor 1) at the cellular level, interfering with its communication pathways that promote cell growth. This disruption is part of why metformin is being studied not just for managing diabetes but also for its potential in cancer prevention and supporting healthier aging.
Effects on Cells and Proteins
Metformin’s primary target within the cell is AMPK (AMP-activated protein kinase), an enzyme that acts as the cell’s energy regulator. When AMPK is activated, it sets off a series of changes that weaken IGF-1’s ability to encourage cell growth and division. One key mechanism involves IRS-1 (insulin receptor substrate-1), a critical player in transmitting IGF-1’s growth signals. Metformin activates AMPK, which then phosphorylates IRS-1, disrupting the IGF-1-driven Akt/TSC1/mTOR signaling pathway. Since this pathway is essential for cell growth, protein production, and survival, metformin effectively slows processes that could lead to uncontrolled cell proliferation.
Another notable effect is metformin’s ability to block the androgen-driven increase in IGF-1 receptor (IGF-1R) expression. Research by Malaguarnera et al. found that metformin reduced cell growth, invasion, and the ability of cells to form colonies by preventing this receptor up-regulation. Additionally, metformin interferes with the interaction between the insulin/IGF-1R and G protein-coupled receptor (GPCR) signaling systems, further altering IGF-1 activity through AMPK activation. These changes collectively reshape how IGF-1 functions at a cellular level.
Changes in IGF-1 Activity and Binding
Beyond cellular signaling, metformin also impacts IGF-1’s availability and activity by modifying its binding proteins. While metformin reduces the overall levels of circulating IGF-1, it also changes how the remaining IGF-1 interacts with cells by increasing the production of IGF-binding proteins (IGFBPs). Specifically, metformin boosts IGFBP2 levels via PPAR alpha activation, a process dependent on AMPK. IGFBPs play a vital role in regulating IGF-1 and IGF-2 by controlling their access to the type I IGF receptor.
The IGFBP family includes six members, each with the ability to either inhibit or enhance IGF-1’s effects. IGFBP3 and IGFBP5 are responsible for most of the IGF bound in the bloodstream, while IGFBP1 and IGFBP2 allow for quick adjustments in free IGF-1 levels during acute changes. By increasing IGFBP2 production, metformin lowers the amount of free IGF-1 available to stimulate cell growth, further moderating its effects.
Effects on Aging and Cancer Risk
These molecular changes have far-reaching implications for aging and cancer prevention. Proper regulation of IGF-1 is critical for healthy aging, as excessive activity can lead to tumor growth and metastasis. Metformin’s ability to reduce IGF-1 receptor activity is particularly valuable in lowering cancer risk. For instance, in endometrial cancer, heightened IGF-1R expression contributes to abnormal cell growth through the PI3K/Akt/mTOR pathway. Metformin’s role in limiting this activity helps mitigate these risks. Research by Sarfstein et al. highlighted metformin’s ability to induce apoptosis and inhibit the growth and migration of uterine serous carcinoma cells, even in cells with mutant p53:
"Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer."
Metformin’s anti-aging benefits are also tied to its effects on the insulin/IGF-1 signaling (IIS) pathway. By improving insulin sensitivity in the liver and reducing IRS2 and IGF1R in neurons, metformin enhances cognitive function. Studies in mice have demonstrated that persistently low IGF-1 levels are linked to longer lifespans, with reductions in IRS2 activity extending lifespan by up to 18%. Animal research has also shown that metformin lowers circulating insulin and IGF-1 levels, effectively suppressing tumor growth in a lung cancer model induced by tobacco carcinogens.
Additionally, metformin supports protein balance by reducing mTOR activity and promoting autophagy, which clears out aging-related proteins. Its ability to lower advanced glycation end products further underscores its potential to extend healthspan.
sbb-itb-cad6158
What This Means for Aging and Health
Metformin's ability to influence IGF-1 levels opens up intriguing possibilities beyond its role in managing diabetes. By modulating IGF-1, this medication could impact aging and disease risk in significant ways. Let’s break down the potential benefits and risks tied to these changes.
Benefits of Lower IGF-1 Levels
Reducing IGF-1 levels with metformin might offer protective effects against certain cancers. For example, women with type 2 diabetes who use metformin could see a reduced risk of breast cancer due to the drug’s ability to slow tumor growth and promote cell death.
Metformin may also support better heart health. It can help address endothelial dysfunction and improve lipid profiles, both of which are linked to a lower risk of age-related diseases and overall mortality.
Risks of IGF-1 Being Too Low
While lowering IGF-1 can have its advantages, taking it too far might backfire. Research suggests that very low levels of IGF-1 could increase the likelihood of metabolic issues, such as diabetes and cardiovascular diseases. This means that over-suppressing IGF-1 might lead to unintended health challenges.
Striking the right balance is essential. While elevated IGF-1 levels are associated with risks like cancer and accelerated aging, levels that are too low could harm metabolic health and increase disease susceptibility. This underscores the need for personalized approaches when considering metformin for uses beyond diabetes care. Properly managing IGF-1 levels is critical to maximizing the potential aging-related benefits of metformin while avoiding its possible downsides.
Research Gaps and What Studies Are Needed
While earlier research has shed light on metformin's effects on IGF-1, there are still many unanswered questions. Existing studies face limitations that prevent clear conclusions about how this medication impacts IGF-1 across various groups and over extended periods.
Problems with Current Studies
One major issue is the small sample sizes and short follow-up periods in many studies, which make it hard to evaluate long-term effects. For instance, the SPIRIT Trial, which focused on metformin's impact on cancer survivors with obesity, provided useful insights but was constrained by its limited scope and 12-month timeline. The trial showed that IGF-1 levels dropped significantly at 3 months, with the effects lasting through 6 months, but levels returned to baseline by 12 months. This suggests that longer studies are necessary to determine whether metformin’s effects on IGF-1 are temporary or can be sustained.
Another challenge is the lack of diversity among study participants. Most research focuses on specific groups, such as cancer survivors or individuals with diabetes, making it difficult to apply findings to a broader population. Age-related differences further complicate the picture. For example, a meta-analysis found that metformin reduced IGF-1 levels in children when used for less than 12 weeks, but it increased IGF-1 levels in adults over 18 years.
Variations in dosage, treatment duration, and participant characteristics also make it hard to compare results across studies. Researchers have pointed out that conflicting outcomes regarding metformin’s impact on IGF-1 levels may be due to differences in study design, participant demographics, and the dose and duration of treatment.
Addressing these gaps is essential for guiding future research efforts.
What Future Studies Should Focus On
To overcome these limitations, future studies need to identify optimal dosing strategies, especially for non-diabetic individuals exploring metformin for its potential anti-aging benefits. Current research uses inconsistent doses, making it impossible to pinpoint the most effective amount for IGF-1 regulation.
Long-term studies are crucial to explore the safety and effectiveness of metformin over extended periods. Since its effects on IGF-1 appear to change over time, research should extend beyond 12 months to determine whether the body adapts to treatment and if sustained IGF-1 reduction is achievable.
Researchers should also consider individual metabolic differences, such as age, gender, and underlying health conditions, which can influence IGF-1 levels. Future studies must stratify participants based on these factors to provide more precise insights.
In addition, mechanistic studies are needed to understand how metformin affects cellular processes tied to its anti-aging potential. Investigating how phosphorylation events interact with cellular pathways could clarify how metformin contributes to these effects.
The reliability of IGF-1 as a biomarker for metformin’s therapeutic effects also requires further validation. Current research highlights the need to establish whether IGF-1 is a dependable measure of metformin’s impact across different clinical populations.
"Before metformin finds its way to mainstay therapy for anti-aging, a clearer understanding of the effects of the drug in humans is needed." – Alexander A Soukas, Department of Medicine, Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital
Given that diabetes and cardiovascular disease account for approximately 22 million deaths annually according to the WHO, understanding metformin’s broader health effects could have far-reaching public health benefits. To achieve this, future research should prioritize large-scale, long-term studies with diverse participant groups and standardized protocols. These efforts will help refine our understanding of metformin’s potential role in promoting healthy aging and maximizing its therapeutic applications.
Key Points About Metformin and IGF-1
Research into how metformin affects IGF-1 levels reveals a nuanced relationship that changes depending on age and how long the treatment lasts. A meta-analysis that reviewed 11 studies involving 569 participants found no statistically significant overall impact of metformin on IGF-1 levels.
Interestingly, the effects of metformin seem to vary by age. For children undergoing short-term treatment (less than 12 weeks), IGF-1 levels dropped significantly - by about 55.4 ng/mL. In contrast, adults over 18 years experienced an increase of approximately 15.1 ng/mL. These differences highlight the importance of considering age when interpreting the data, as they suggest more complex underlying biological mechanisms beyond direct IGF-1 regulation.
Metformin's anti-aging potential is thought to go beyond its influence on IGF-1. The drug activates AMPK and inhibits mTOR - two key regulators of cellular processes like metabolism, growth, and inflammation. These actions contribute indirectly to its anti-aging effects . Additionally, metformin’s benefits are linked to its ability to lower blood sugar, improve insulin sensitivity, reduce oxidative stress, and support vascular health.
However, safety considerations make medical oversight essential. While metformin is FDA-approved for type 2 diabetes, long-term use can lead to vitamin B12 deficiency in 6% to 30% of users. Gastrointestinal side effects affect 20% to 30% of individuals, and the drug can increase lactate levels, raising the risk of lactic acidosis - particularly in patients with kidney issues.
With ongoing trials like MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin), anyone considering metformin for IGF-1 regulation or anti-aging purposes should consult a healthcare provider. Individual responses can vary widely, making professional guidance crucial to balancing potential benefits with risks.
FAQs
How does metformin affect IGF-1 levels in children compared to adults, and what are the implications for its use?
Metformin's effect on IGF-1 levels varies significantly between children and adults, which plays a key role in how the medication is applied across different age groups. In children, metformin tends to lower IGF-1 levels. This reduction can support growth regulation and help manage conditions like PCOS or specific growth hormone disorders.
On the other hand, research indicates that in adults, metformin often raises IGF-1 levels. This increase may promote anabolic effects, offering potential advantages for healthy aging and addressing age-related conditions.
These contrasting effects underscore the need to adjust metformin use based on age and individual health factors, especially when considering its influence on growth and metabolic functions.
How does metformin affect IGF-1 levels, and why is further research important?
Metformin seems to interact with IGF-1 levels in a rather intricate manner. Some research indicates that it might slightly lower IGF-1 levels or influence its activity indirectly. This could happen through its ability to reduce insulin levels and modify IGF-binding proteins. Since IGF-1 is deeply involved in growth, longevity, and cellular health, these effects might have a connection to aging and age-related conditions.
That said, the research isn’t entirely consistent. Results often vary based on factors like the metformin dosage, how long it’s used, and the health status of the individuals studied. To truly understand how metformin affects IGF-1 in the long run - especially in relation to healthy aging and disease prevention - further studies are essential.
How does metformin dosage impact IGF-1 levels, and what factors influence finding the right dose for each patient?
Research indicates that metformin's effect on IGF-1 levels is closely tied to the dosage. Daily amounts between 500 mg and 2,000 mg have been associated with lowering IGF-1, which might contribute to its potential benefits for aging and metabolism. However, individual responses can differ.
Finding the right dose depends on several factors, including kidney health, how well the medication is tolerated, and personal health objectives. While doses as high as 2,550 mg per day are often considered safe for many people, adjustments should always be tailored to the individual’s needs and overall condition. Routine check-ins with a healthcare provider are crucial to ensure both safety and effectiveness.
